\nMinisterul S\u0103n\u0103t\u0103\u0163ii din Japonia a aprobat mar\u0163i un nou medicament, dezvoltat de Eli Lilly pentru tratarea bolii Alzheimer, ceea ce le d\u0103 pacien\u0163ilor o alternativ\u0103, scrie Reuters.<\/p>\n
\nAceasta este a doua pia\u0163\u0103 major\u0103 care aprob\u0103 medicamentul celor de la Eli Lilly, dup\u0103 Statele Unite, unde este comercializat sub numele de Kisunla.<\/p>\n
\n\u00cen Japonia, peste 4,6 milioane de persoane sufer\u0103 de demen\u0163\u0103, num\u0103r ce se a\u015fteapt\u0103 s\u0103 creasc\u0103 pe m\u0103sur\u0103 ce popula\u0163ia \u00eemb\u0103tr\u00e2ne\u015fte, conform Asocia\u0163iei Alzheimer.<\/p>\n
\nKisunla este conceput pentru a elimina proteina beta-amiloid asociat\u0103 cu Alzheimer din creier, la fel ca Leqembi, un alt tratament aprobat \u00een Japonia anul trecut.<\/p>\n
\n\u00cen cadrul unui studiu clinic de faz\u0103 avansat\u0103, Kisunla a demonstrat o \u00eencetinire a progresiei problemelor de memorie \u015fi de g\u00e2ndire cu 29% fa\u0163\u0103 de placebo.<\/p>\n
\nCu toate acestea, tratamentul a cauzat umfl\u0103turi cerebrale la aproape un sfert dintre pacien\u0163i \u015fi hemoragii cerebrale la o treime, de\u015fi cele mai multe cazuri au fost u\u015foare.<\/p>\n
\nUn avantaj al Kisunla fa\u0163\u0103 de Leqembi este dozarea finit\u0103, permi\u0163\u00e2nd pacien\u0163ilor s\u0103 opreasc\u0103 tratamentul odat\u0103 ce scan\u0103rile cerebrale nu mai arat\u0103 pl\u0103ci amiloide.<\/p>\n
\nAprobat cu un avertisment de siguran\u0163\u0103 din partea FDA, medicamentul ridic\u0103 riscuri similare cu cele asociate Leqembi, dar ofer\u0103 speran\u0163\u0103 \u00een fa\u0163a celei mai comune forme de demen\u0163\u0103, Alzheimer, care reprezint\u0103 60%-70% din cazuri la nivel mondial.<\/p>\n","protected":false},"excerpt":{"rendered":"
O companie farmaceutic\u0103 a primit aprobarea \u00een Japonia pentru tratamentul Kisunla, \u00eempotriva Alzheimerului, o alternativ\u0103 la Leqembi.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[36542,105],"class_list":["post-230360","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-alzheimer","tag-japonia"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/230360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=230360"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/230360\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=230360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=230360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=230360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}